Fusion proteins
US9855318B2 · kind B2 · utility
19Cited by
12References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2016 |
| Grant date | Jan 2, 2018 |
| Priority date | — |
| Expiry date | Apr 28, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.